Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Current Assets (2023 - 2025)

Historic Current Assets for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $279.9 million.

  • Immunome's Current Assets rose 1470.41% to $279.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $279.9 million, marking a year-over-year increase of 1470.41%. This contributed to the annual value of $221.3 million for FY2024, which is 5296.09% up from last year.
  • Per Immunome's latest filing, its Current Assets stood at $279.9 million for Q3 2025, which was up 1470.41% from $277.4 million recorded in Q2 2025.
  • Immunome's Current Assets' 5-year high stood at $323.1 million during Q1 2025, with a 5-year trough of $39.5 million in Q2 2023.
  • For the 3-year period, Immunome's Current Assets averaged around $206.0 million, with its median value being $244.0 million (2024).
  • As far as peak fluctuations go, Immunome's Current Assets soared by 61923.29% in 2024, and later plummeted by 241.03% in 2025.
  • Over the past 3 years, Immunome's Current Assets (Quarter) stood at $144.7 million in 2023, then soared by 52.96% to $221.3 million in 2024, then rose by 26.47% to $279.9 million in 2025.
  • Its last three reported values are $279.9 million in Q3 2025, $277.4 million for Q2 2025, and $323.1 million during Q1 2025.